Results 11 to 20 of about 3,958 (169)

Dyslipidemia causes overestimation of plasma mitotane measurements

Endocrinology, Diabetes & Metabolism Case Reports, 2016
Mitotane (o,p′-DDD) is the standard treatment for advanced adrenocortical carcinoma (ACC). Monitoring of plasma mitotane levels is recommended to look for a therapeutic window between 14 and 20mg/L, but its positive predictive value requires optimization.
Angelo Paci, Ségolène Hescot, Atmane Seck, Christel Jublanc, Lionel Mercier, Delphine Vezzosi, Delphine Drui, Marcus Quinkler, Martin Fassnacht, Eric Bruckert, Marc Lombès, Sophie Leboulleux, Sophie Broutin, Eric Baudin   +13 more
doaj   +2 more sources

Generation and characterization of a mitotane-resistant adrenocortical cell line [PDF]

Endocrine Connections, 2020
Mitotane is the only drug approved for the therapy of adrenocortical carcinoma (ACC). Its clinical use is limited by the occurrence of relapse during therapy.
Eric Seidel, Gudrun Walenda, Clemens Messerschmidt, Benedikt Obermayer, Mirko Peitzsch, Paal Wallace, Rohini Bahethi, Taekyeong Yoo, Murim Choi, Petra Schrade, Sebastian Bachmann, Gerhard Liebisch, Graeme Eisenhofer, Dieter Beule, Ute I Scholl   +14 more
doaj   +2 more sources

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma [PDF]

Cells, 2020
Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism.
Antonina Germano, Daniela Rossin, Valerio Leoni, Noemi Iaia, Laura Saba, Vittoria Basile, Soraya Puglisi, Claudio Caccia, Giuseppe Poli, Fiorella Biasi, Massimo Terzolo   +10 more
doaj   +2 more sources

Clinical results of the use of mitotane for adrenocortical carcinoma

Brazilian Journal of Medical and Biological Research, 2000
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synthesis. Its adrenolytic effect depends on metabolic activation due to conversion to o,p'-DDA and o,p'-DDE.
A.A. Kasperlik-Zaluska
doaj   +2 more sources

Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study [PDF]

International Journal of Endocrinology, 2013
Limited data are available about mitotane-nduced hyperlipidemia. We retrospectively analyzed lipid data in 38 patients with adrenocortical carcinoma (ACC) who received mitotane therapy with emphasis on HDL cholesterol (HDL-c) and clinical predictors of ...
Hassan Shawa, Ferhat Deniz, Hadil Bazerbashi, Mike Hernandez, Rena Vassilopoulou-Sellin, Camilo Jimenez, Mouhammed Amir Habra   +6 more
doaj   +2 more sources

Mitotane Treatment for Malignant Leydig Cell Tumor: A Case Report

IJU Case Reports
Introduction Leydig cell tumors (LCTs), constituting 1%–3% of testicular tumors, are mostly benign, but malignant cases present treatment challenges. We report a malignant LCT case with a notable response to mitotane. Case Presentation A 43‐year‐old male
Daiki Katsura, Mototsugu Muramaki, Takashi Okamoto, Masaya Yamamoto, Mizuki Yutaka, Shohei Morita, Takuya Fujimoto, Yuji Yamada   +7 more
doaj   +2 more sources

Development and application of a beta-tritium-mitotane assay for studies on the mechanism of the adrenolytic action of mitotane.

, 1994
The toxicity of mitotane limits its use in the treatment of adrenal cancer and Cushing's disease. Because of this limitation and because some patients are refractory to mitotane, our current research is directed towards the synthesis of mitotane analogs ...
Pineiro-Sanchez, Mayra Lyz
core   +7 more sources

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat. [PDF]

Br J Clin Pharmacol
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
van Ton AMP, van Erp NP, van de Ven AC, Walraven JEW, de Jong LAW.   +4 more
europepmc   +2 more sources

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma [PDF]

, 2022
INTRODUCTION Adrenocortical carcinoma (ACC) is a rare aggressive cancer with low overall survival. Adjuvant mitotane improves survival but is limited by poor response rates and resistance. Mitotane's efficacy is attributed to the accumulation of toxic
Lim, Yi Jan, O'Shea, Paula, Ribes Martinez, Eduardo, Hantel, Constanze, Dennedy, Michael Conall; https://orcid.org/, Beuschlein, Felix; https://orcid.org/, Warde, Kate M; https://orcid.org/   +6 more
core   +1 more source

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α

Biomedicines, 2021
Mitotane is the cornerstone of medical treatment of adrenocortical carcinoma. Estrogenic-like side effects frequently occur in patients, and previous studies explored the chemical nature of the interaction between estrogen receptor-α (ER-α) and toxic ...
Elisa Rossini, Edoardo Giacopuzzi, Fabrizio Gangemi, Mariangela Tamburello, Deborah Cosentini, Andrea Abate, Marta Laganà, Alfredo Berruti, Salvatore Grisanti, Sandra Sigala   +9 more
doaj   +1 more source